NERV Minerva Neurosciences, Inc.

NASDAQ
$2.16

Minerva Neurosciences, Inc. Q3 F2026 Earnings Call Transcript

AI Conference Call Analysis

Sign in or subscribe to read.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Good morning, everybody. It's really a pleasure and honor to have you here on behalf of the Minerva team. Most of my colleagues are here, so after these presentations, when we have something to eat afterwards, don't hesitate to go to see them, to speak with them. It's really an honor to have you here to really, I think, present you something which is very important. As you know, since 70 years, People have tried hard in order to improve negative symptoms of patients suffering with schizophrenia. And I think here today we have Roliparidone, which is really, really creating some hope for patients. And as you know, we are all here in order to come up with better treatments for patients. So this is what we will go through today to give you an update about where we are and where we are going. And if it is moving. It is moving. So because you're a public company, I have always to show this slide. But I think it's just to mention that we are a public company. And if you want to know more, you have to go to our filings, SEC filings. So I have really the great pleasure to have with us three persons who have been extremely important for the space. So I have the honor to have Dr. Strauss, Greg, yes, because we are working together since quite long, yes, allow me to call you Greg, yes, but Greg, you will see, has worked on our data, has analyzed our data, and he has obviously a very broad knowledge about the space, but I will not go more into the details because his CV is too long, and he will present his research when he will speak. The second person could not make it to today. It is Dr. Brian Kirkpatrick. And Brian will also speak. And Brian is really, I think this is really amazing because Brian is really, really an incredible researcher, but he kept really the contact with patients. He sees patients on a daily basis and he will tell us about how these patients are looking like, how he sees his patients. I mean, we are targeting with rhodoperidone in his clinical practice. And last but not least, we have Dr. Carell and Christoph is, as you know, I mean, it's no need to present him. He's an amazing person and he has really contributed a lot to the space. So we will have a Q&A session so you can ask all the questions to my three colleagues here speaking. What we will address today is a quite large program. So first, I will give you a refreshment about Roliparidone, where we are with Roliparidone. Also an update, a peak update on the C19 study because the study is ongoing. And afterwards, I hand over to Greg, to Dr. Strauss, who will speak about how important primary negative symptoms are as We will not go into the details about primary secondary negative symptoms because Dr. Strauss could speak a lot about it and he will explain how important they are in order to give some hope to patients. Dr. Kirkpatrick will speak about, again, as I said, his view on our patients, why these patients are not keen to relapse or have limited relapses, and how he sees his patients in his clinical practice. I will go quickly through some new analysis because we continue to work on our data. Just to better understand the data, to better characterize the patient population, to better characterize rhodoperidone. And you will see we have quite exciting data. And we have here in the room, Jonathan Rabinovich and Michael Davidson who have worked on this. And if you have questions, they are more than happy to answer the questions. and after that we conclude with giving you a flavor about what is a market opportunity and afterwards we open for Q&A. I wanted also to mention that we have the chance to have my friend Frank who is here because Frank has been from the beginning of this journey and he's really guiding us through how to bring over the message to the FDA, to the regulator of this paradigm shift, yes, because we are speaking here about the paradigm shift. And I hope that at the end of the presentation, you will see that indeed what you're doing here is a paradigm shift. And as you know, when you're changing something in clinical practice, when you're coming up with new ideas, it's always a little bit challenging, but we are getting there because I think Roliparidone could really be the first drug approved for negative symptoms. So very quickly, A few words about what we're doing here. So just to re-emphasize the fact that negative symptoms are really central. It's really central when we are thinking about giving a solution or providing a treatment for patients with schizophrenia. I will not focus on all these primary, secondary negative symptoms because I think Greg will cover this much better than me. I wanted to focus just on the figure on the top right, by the way, published by Dr. Carell. And just to mention that it's maybe obvious for everybody, but it's important. You have three types of symptoms when you're dealing with patients suffering from schizophrenia. You have the positive symptoms, materialized or shown by these green lines. You know, you have some acute phases of positive symptoms, what we call relapses of positive symptoms. And afterwards, when the disease is aging, these positive symptoms are less bothering, are less frequent, are really no longer really a big problem. This is what we're currently treating with antipsychotics. We are really focusing on treating positive symptoms. You see that we have two types of other symptoms, the cognitive deficit, which is materialized with the blue line here. And this is a type of symptoms which are present all along the life of the patient. And we have negative symptoms in the brown line. Again, you will hear a lot about negative symptoms, but just what I wanted to mention on this slide, look, what Christoph put is a level where disability starts to kick in. And when you see when disability starts to kick in, it is really when negative symptoms are becoming a real problem. So really, I think it's very clear to everybody that if we want to give a chance for patients to have a decent family life, to have a We need to find a solution for negative symptoms. Just to make my case here, as we know very well, it is very well described in the literature and there are some references here at the bottom. It is really negative symptoms, not the positive symptoms, which are really the primary drivers of the disability in patients. This is a very schematic way to present things. It's clear that if you're able to improve negative symptoms, probably you're able to improve the daily functioning of these patients. And you will see that in our studies, we have really always measured the daily functioning using a scale which is called the PSP scale and obviously improving quality of life. And I think what speaks very well here, and I'm always taking this example, you know, it's now 70 years or so that we have antipsychotics. And again, don't take me wrong, antipsychotics are very important. They are very important in our ammunition in order to help these patients. But when you're looking to how many patients have a job, Nothing has changed since 70 years. And when you see that 80 to 90% of these patients have no job, compared to four or five percent to normal people, definitely, I mean, there is something which has to be done. And again, probably improving negative symptoms, but probably also improving primary negative symptoms is definitely important. Coming to Roliparidone. This slide shows that it takes a little bit of time. This is the pharmacology of rhodoperidone. I wanted just to give you the rationale how we designed rhodoperidone. The first objective was to get rid of a direct dopamine blockade. This was the first objective because we know that blocking dopamine is very important for antipsychotics to help to treat an acute episode of psychosis or positive symptoms, but we know also that by doing so, you're inducing a lot of side effects. And we're always forgetting sometimes the side effects, but when I think Michael showed me a recent study, the reason why patients are really willing to stop the treatment is because they're bothered with side effects. Obviously, they have also the psychotropic effects, but they are really bothered with side effects. So it's really a problem. Roliparidone has no direct blocking effect on dopamine. It is definitely modulating dopamine, and I will not go into the details because it would be too long, but definitely it's not blocking dopamine. The three targets we have here is serotonin. We are targeting the sub-receptors, which is called the 5-HE2A receptor. It has an antagonistic activity there. The Sigma-2 receptor, which is a less known pathway in the brain. but definitely in my opinion and based on my clinical observations you know developing quite a lot of drugs in my life the sigma activity is probably one of the key drivers of explaining why our drug is improving negative symptoms and you will see probably primary negative symptoms and afterwards you have also and Alpha-1 adrenergic activity. So it's always difficult to say this target is doing this, but I think the combination of the three targets is definitely explaining the uniqueness of Rhodipiridin. And last but not least, we have done a lot of work to better understand what is going on. So for example, in terms of nerve growth factors and For the moment, it is preclinical, but I mean, it's very, very compelling data. We can demonstrate that Roliparidone is inducing a huge increase in transcription of BDNF and GDNF and also the release of BDNF and GDNF. And think one second, I mean, these nerve growth factors are really, really important in neuroplasticity to restore neuroplasticity. So this is what is about Roliparidone. And it has been designed on purpose. Now, let's see if all these hypotheses are translating into what we have seen in clinical practice. Here, it's very summarized, because the objective is not to go through all the data. It's more important that my colleagues are speaking afterwards. But what you can see in terms of efficacy, so in all the two studies, we have run two studies, which one is called CSEROS-3 study, The other one, CSERA 7 study. We have measured negative symptoms using the PAN scale, which is a gold standard. And when you're looking to the negative score, which has been proposed by Professor Marder, which is called the NSFS score, you see that the first study, the CSERA 3 study, No-brainer, I mean, 64 mg showed a very, very strong difference compared to placebo after 12 weeks of treatment in monotherapy. So keep in mind that here the patients are not staying on antipsychotics. They are really treated in monotherapy for 12 months. What you can see is that in the CSERA 7 study, we still have for 64 mg, which was the highest dose we tested, a p-value. which is obviously going down because a larger study more clinical sites that we have still a p-value and what we also merit because this is important and we will hear a lot about functioning We measured functioning using the PSP scanner. And what you can see here, again, in the two studies, we could demonstrate that indeed, looking to daily activities, because PSP is a very practical scanner, so looking to daily activity, indeed, you can see that these patients are, when they're improving the negative symptoms, they're also improving their daily functioning. And obviously, last but not least, what is important, Is this drug safe in terms of relapses, you know, when you give it in monotherapy? Because, again, the paradigm shift here is to say there is a subpopulation who does not need continuous treatment with an antipsychotic. Obviously, the pharmacology of Roliperidone might help, but what happens in terms of relapses? So the green boxes or the green bars you can see, these are the results we obtained in terms of relapses in the two studies we have run, the C03 study and the C07 study. You can see this is over 12 weeks, plus 24 weeks for the C03 study, and plus 40 weeks for the C07 study. And Jonathan did a comparison by selecting from A database which is called the KT database. I think it's familiar to everybody. It is the largest database which has been generated in the US with antipsychotics. He extracted the patients who have the same eligibility criteria as the one we have in our two studies. And you can see what is the relapse rate you see in patients who are getting antipsychotics. So it's not the final say here, but I mean, it's clear that The patients we have recruited in our studies and the patients we are currently recruiting in our C-19 study seem to be less keen to relapse. And we'll hear much more about it, why we might think that this is the case. So this is a study. So I think everybody has seen the study design. This study is really coming out of all what we learned from the previous studies with in-length and very productive discussion with the FDA. And I have to say that we had really, really good interactions, good advice. And I think it's fair to say that this is somehow the consensus of what we have to do here. So the first thing we have to do, because keep in mind that this is a large patient population we are addressing, we have What is called phase A of the study, the first 12 weeks, you see, this is to really confirm what we have seen in terms of efficacy with the two previous studies. The big difference here compared to the two previous studies is that we are focusing on 64 mg, which is the dose for which we are seeking an approval. and we have no longer 32 mg in this phase. So the objective here is really to demonstrate that indeed using the NSFS endpoint, so the negative symptom endpoint we have used in the previous studies, we show a p-value between placebo and treatment and 64 mg. What we call phase B, this is really different from what we have done in the two previous studies. In the two previous studies, the patients were allowed to go into an open label extension, so everybody was switched to treatment. In this case, and this is really something which has been discussed with the FDA, and I think it's very important. Also, it will be purely descriptive because the number of relapses we have does not allow you to do any formal statistical analysis. It will be purely descriptive. but it's a comparison between our patient populations, the patients we have recruited in our studies, the patients we are recruiting in the C19 study, when they are receiving an antipsychotic, we will check the relapse rate and we will compare it to the relapse rate we see with Ronyperidone. This is important to reassure patients to reassure the patients, to reassure the prescriber, to reassure the agencies that indeed, I mean, there is nothing severe which happens when you take off this patient population from antibodies. And we will hear much more about this from Dr. Kilpatrick. So this is basically the study. So I will not go into the details of where we are with the study. We are really enrolling the patients. The study is going according to plan. As we have disclosed, we really hope that we will have the results in the second half of next year. Today, definitely, we are on track to have the results coming out. I'm speaking obviously about the first 12 weeks, that's about phase A, during the course of second half of next year. I will be not very long on this slide just because this is too complicated, too busy. But it's just to say that the study design we have implemented here is not just because we wanted to do it in this way. It was really done by really thinking what we are trying to achieve here. First of all, we wanted to demonstrate that we have an effect on primary negative symptoms. So primary meaning disease-related negative symptoms. and so here you know you need to avoid patients who are fluctuating too much and so you're looking to stability of these patients over the last six months before there are candidates for the studies they need obviously to have negative symptoms which are impairing in order to be to be part of the study but just to mention that the You go to the literature, and I'm using the word Michael is always telling me, and he knows the literature in and out, Dr. Davidson, it's a graveyard to put drugs on top of antipsychotics because you're blocking dopamine and the things that are likely to improve negative symptoms is difficult. I'm not saying that it is not possible, but we have decided to focus on a subpopulation where we think that there is more stability in order to really demonstrate that first ronipiridone has an effect on primary negative syndrome. When the drug will be approved, we can really think about moving forward. So when you're looking to the conclusion of all this work, and even there was a committee at the IACTM meeting who was working on study designs, I think it's fair to say that probably the best study design is monotherapy, long period enough, stable patients. And because there is no approved drug, in terms of negative symptoms, the comparator is placebo. The last thing which is coming on the last slide before I hand over to Dr. Strauss, I wanted really to make something very clear because I'm obviously reading all the reports, I'm reading all what is published and a lot of people say, okay, I have an effect on negative symptoms. This slide I think is to explain that you have Two things. You can improve primary negative symptoms. So this is a brown line. So basically, you're reproducing the brown line, which was also in the slide from Dr. Carell. So this is what we call, technically, this is a trademarker. So this is a marker. These are symptoms which start very early on and are present all lifelong of the patient's life. and afterwards you have what we call state markers. These are markers or symptoms when you're looking to the patient today. So one day the patient can show some depressive disorders, one day he can be bothered with extra-premordial symptoms, his motor symptoms because his treatment is not completely adapted and sometimes these patients have an acute relapse of positive symptoms which is a green light at the bottom. When you bring down from this acute episode the patient, this is what we call a pseudo-improvement. So you're improving or you're bringing back the patients to the level of their primary negative symptoms, of their disease negative symptoms. So I think the only way to claim that you have really an effect on primary negative symptoms is to do what you're doing. Stable patient, long-term effect patient. and all the rest is all maybe to improve negative symptoms, but to bring someone down from an acute episode is to the effect, to the improvement of negative symptoms. So it's very important so that we understand about what you're speaking. I think it's time now to hand over to Greg.
Gregory Strauss
Professor of Psychology and Neuroscience, University of Georgia
Good morning, everyone. It's a pleasure to be here. I'm Dr. Gregory Strauss. I'm a professor of psychology and neuroscience at the University of Georgia. And my research over the last 20 years or so has focused on negative symptoms, in particular, the phenomenology or how we conceptualize them, developing new assessments for negative symptoms, understanding their mechanisms from a neurobiological perspective. and of course working on new treatments. And there's also always a beautiful irony of having negative symptoms be your scientific expertise. I'm very motivated to study the lack of motivation. I enjoy studying the inability to experience pleasure. And of course, I'm excited to talk to you about some of our new work on this today. So as Dr. Luthringer set up so beautifully, Negative symptoms are heterogeneous. In other words, you can have two patients with the exact same score on a negative symptom clinical interview scale like the PANS for very different reasons. For example, they may both have a score of 20 on the PANS. One patient may be predominantly apathetic. We call this primary negative symptom. It's something that's assumed to be a direct manifestation of the illness of schizophrenia itself. You can have another patient who looks identical on paper, but their negative symptoms are secondary. They result from other factors. And this is not a concept specific to negative symptoms or even psychiatry. It's known throughout medicine. I'll give you a brief example. Last summer, I took my daughters to Orlando. We went to Disney World. We were very excited until we got home to this rental house at the end of the first night. My younger daughter, seven years old, wanted to go downstairs and get a drink. Daddy went downstairs with no contacts in. I went one way. My body, my ankle went the other way. Snap, snap, later. I can't walk for a few days. Fast forward a couple of months. I go to the doctor and I say, my knee is hurting. And looks at the knee. Nothing's wrong with the knee. She says, this is secondary. You need to improve your ankle. You've not rehabilitated your ankle. You went back to your normal level of exercise too quickly. In psychiatry, it's a similar idea. The idea is that there are common problems There are common secondary sources of negative symptoms. Sorry, screen went forward on me. There are several common secondary sources of negative symptoms, and two of them are depression and anxiety. For example, someone may be incredibly sad, feeling worthless. They may have sleep problems. These may cause them to have a lack of recreational activity, goal-directed social behavior. Another person may be very worried. They may be very tense in their expression of emotion in the face and look very blunted. They may be so concerned about the things they're worrying about that they don't seek out social or goal-directed activities. This is very different from someone with true or primary negative symptoms. These patients will not feel depressed or anxious regardless of what is happening to them, regardless of the stimulus. For example, a case where a patient's brother passed away. They were living with sharing a room with the brother. They did not feel sad. They did not feel depressed at all after losing the brother. Anxiety, same thing. Another patient with this primary negative symptom profile was held up at gunpoint. Remarkably terrifying experience for anyone. Did not feel fear in this situation. No anxiety, right? So this is a very different profile, this secondary negative symptom profile, than what happens with primary negative symptoms. Similarly, positive symptoms can induce negative symptoms as a secondary cause. for example, hallucinations. So when they hear a voice telling them, don't get up off the couch or the FBI will come and chop your legs off and you'll die. So they sit on the couch, they don't engage in activities and They're behaviorally delusional. Same thing. They may be paranoid, thinking others are out to harm them. So they withdraw socially as a protective mechanism. Or they may be so disorganized in their thought that they can't execute goal-directed activities to engage in motivated behavior. This is not a primary negative symptom. People with primary negative symptoms have very low levels of positive symptoms, low levels of hallucinations, delusions, disorganization. So without having any of those positive symptoms at a severe level, they still have negative symptoms. They still withdraw socially. They're not interested in the social interactions. They could take it or leave it. They don't feel lonely, even though they've spent the majority of their time alone during the day. This is a very different profile. Similarly, medication side effects. Someone might be sedated due to the effects of their antipsychotic. This may cause them to have less behavioral activation. Someone with primary negative symptoms, they continue to show the lack of behavior even in periods where they're medication-free. So their negative symptoms persist even into these medication-free periods. So Creating, importantly, there are a couple of very critical things to know about this primary-secondary distinction. The first one is primary and secondary phenotypes have distinct underlying mechanisms. We have estimated that primary negative symptoms largely result from disrupted corticosteroidal circuitry. that is driving this apathetic profile. Secondary negative symptoms, on the other hand, have different underlying biological factors that travel with the secondary sources. They travel with mood, anxiety, positive symptoms, et cetera. Now, because of these distinct underlying mechanistic profiles, point number two is really critical. Treatments targeting secondary sources. often reduce negative symptoms in patients with secondary phenotypes. In other words, if you have a patient who's depressed, treat the depression. If their negative symptoms are driven by anxiety, give them an anxiolytic. Not in every case, but a good percentage of the time, the negative symptoms will improve as these secondary sources improve. This is the pseudo-specificity that Remy was talking about a moment ago. The negative symptom effect is essentially a byproduct, if you will, of improving these secondary sources. The third point is that treatments targeting secondary sources do not reduce negative symptoms in patients with primary phenotypes. Treating patients with a primary phenotype with antidepressants, anxiolytics, will not improve their negative symptoms. It's the wrong mechanism. The mechanism is distinct and not being hit by that compound. Fourth. treatments targeting primary negative symptoms are not expected to reduce negative symptoms in patients with secondary phenotypes. Essentially, again, another mismatch between mechanism and mechanism of action of the drug and the underlying mechanism in the patient. So what does this tell us? The treatment of primary negative symptoms is the holy grail. This is something that has not been addressed in the literature to date. There are strategies for addressing secondary negative symptoms, But not primarily. And they're critical because, of course, for many reasons, but they're tied to lower rates of recovery, poor functioning, lower well-being, greater stress on the family and caregivers. So this is really, as others have termed, the holy grail of psychiatry, is to find a treatment for primary negative symptoms. So, of course, the critical question becomes, is Rolo Peridon doing this? The short answer is yes. On the screen in front of you, what you see is data from a probability calculator that estimates the extent to which someone's negative symptoms reflect primary or secondary causes. Now, if you look at the figure on your left, primary negative symptoms are displayed. And what this is is an algorithm we developed called the primary stability weighted score. And what this is is essentially an estimate of the severity of someone's primary negative symptoms weighted by How persistent they are over time from baseline to the end of the study. So here, higher values mean that the negative symptom is more primary and more persistent, right? What you see here is that placebo has higher primary and persistent scores. then Roloperidone. This is exactly what you would want if the drug is treating primary negative symptoms. Placebo is going to be consistent across time. Their negative symptoms are not changing. They're primary. They don't fluctuate. They're enduring trait-like features. When given Roloperidone, the patient's who are responding are the ones with this primary phenotype. Their negative symptoms become both less severe, the primary negative symptoms become less severe and less enduring. So you can see that indicated by the lower scores there for roloperidone than placebo. Now, if you're not familiar with looking at these types of charts, a handy way to know if something is statistically significant is to not just compare the height of the bars, but also to look at the overlap in the standard error bars. So you can see the error bars here have minimal or potentially no overlap. And that is indicating a greater likelihood of statistical significance. So you can see in this particular metric, the p-value is 0.03, so less than 0.05. In contrast, the secondary score did not significantly differ. So you can see here the p-value is 0.61. Now the secondary score is a little bit different. First thing to know is that it's on a different scale than the primary score. The figure is also very zoomed in. So it's also on the axis is a little bit centered differently. But what this scale score represents is essentially the likelihood that someone's negative symptoms are driven by secondary factors like anxiety, depression, paranoia, hallucinations. and how dynamic they are over time. Because remember, secondary negative symptoms are transient. They fluctuate a lot as those secondary sources vacillate across time. They're inherently unstable. So this score weights not only how secondary the patient is, but how inconsistent or unstable their scores are across time. And what we see here is that placebo and riloperidone do not differ. And that's suggesting that the drug is not having an effect on secondary negative symptoms, but of course it is on primary. And again, this is really the holy grail of psychiatry, of showing an improvement in primary negative symptoms. Now, importantly, that's not a given. I would argue that prior studies, if they have reported an effect on negative symptoms, many of them have, if not all, have been really driven by pseudospecificity and these improvements in secondary factors. So this is something that is really an important finding. Now, another key thing that we have found with Roloperidone is addressing what is driving the effect. And I don't mean at a neurobiological level. We know the components of the drug. I'm talking about in terms of a symptom network level interaction. Many clinicians think of individual symptoms as being distinct entities, but that's not correct. Just like almost any other element, of the environment, things interact, symptoms can interact. For example, why would someone not show emotion in the face? Why would they not speak? Why would they not engage in social activity? Maybe they don't enjoy those things. Maybe there's an underlying factor driving. Maybe it's a hedonic deficit. Maybe the way to treat that deficit would be to hit that component, right? And you would see a cascading effect temporally where all the other domains would improve. You could make another hypothesis that maybe it's social function. These are people who've been devoid of social interaction for years. and maybe the drug achieves its effect by making them more social. So then they have more opportunities to speak, become more expressive, more motivated in general. So there are many possible interpretations. The one we hypothesized, however, was neither of those. It was that the drug achieved its effect by hitting a key mechanism of abolition or a reduction in motivation, right? So what actually was found here using these network analytic approaches is that when the drug improved the negative symptom constellation, it first hit motivation. Once motivation improved, there was a subsequent cascading effect across time where all of the other domains improved. So motivation is highly central to the improvement of the entire negative symptom constellation. And this was data from the C03 study. We subsequently replicated this effect in the C07 study. This is a similar but more recent network analytic approach and intervention network analysis. These algorithms are changing every six months. There's something new out there, so we applied one of the newer ones. And what we found is that there's actually a direct effect of the treatment on the PANS item most similar to avolition. which is called emotional withdrawal. So in other words, the drug effect was hitting this item related to abortion. And again, it produced this cascading effect where you saw subsequent improvements in the other negative symptoms. So a replication of the phase two C03 study findings. Now hang with me. Why does this matter? Why do these network approaches matter? Who should care about this? I would argue that these are perhaps some of the most critical findings. Why do any of us do anything we do throughout the day? Our motivational system is functioning. Why do you change your clothes? Why do you go to work? Why do you have romantic relationships, friendships? write checks, motivation is a critical component of this. Without it, these activities become much more difficult to activate. One reason that this network finding matters is because of this graph here. In both the C03 and C07 studies, what you see is an improvement of functioning, of role and social functioning for roloperidone compared to placebo. So it improved these aspects of daily life, such as doing chores, getting to your appointments, having friendships, romantic relationships. And this is not a given, right? It's possible to change motivation, but not change these critical behaviors. It may be that someone wants to do them, but they don't do them in the real world. And that was not the case here. With Rola Peridot, you see You see that with this effect that happens on motivation, there's a subsequent effect on functional improvement. So motivation may be important to change because of its critical relationship with functioning. To give you an easy way to remember this, What is the importance of abolition or motivation here? Why does the entire constellation of negative symptoms improve? You change motivation. You make people want to speak more. You make them more likely to be expressive. You make them more likely to interact socially, to engage in pleasurable recreational activities. Interestingly, you can also improve their cognition. One of the key findings previously published on roloperidone is that it also improves basic neuropsychological test performance. And motivation is also a critical aspect of cognitive impairment. You have to be motivated intrinsically to do well on these tests to have a good performance. So changing motivation may be critical. Improving cognition in tandem may actually also be critical for improving motivation. It may allow you to have better executive functioning to execute goal-directed activities better. So why is riloperidone important from a clinical perspective? it's improving all of these aspects of negative symptoms that are critical through this effect on motivation that has the subsequent improvement on the two critical unmet needs in schizophrenia therapeutics, cognitive impairment and functional outcome, right? These are really important for improving the quality of lives that patients have and making them more likely to recover and do better in life. So again, Primary negative symptoms are really important as one take-home message, and roloperidone is indeed changing primary negative symptoms but not secondary, and it's achieving this effect through a direct improvement on motivational processes that are important for improving functioning. And I will stop here and pass it back to Dr. Luthringer.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Thank you so much, Rick. Yeah, so now it's my pleasure to introduce Brian. So Brian is sitting in a very nice location, yes? Brian, the floor is yours, so I don't know, do I have to change the slides? Okay, so Brian, you tell me when I have to change your slide, yeah?
Brian Kirkpatrick
Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences
Thank you. I'm Brian Kirkpatrick. I'm a professor in the Psychiatric Research Institute of the University of Arkansas for Medical Sciences. And throughout my career, I have focused on research and clinical care on people with psychosis. Next slide. So I'm going to be talking about clinical issues for patients with primary negative symptoms. give you some more idea of who these patients are, then talk about whether monotherapy is safe or even beneficial for some people, and what are the consequences of treating negative symptoms.
Gregory Strauss
Professor of Psychology and Neuroscience, University of Georgia
Next slide.
Brian Kirkpatrick
Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences
So this is a very distinctive group of patients. There's been a lot of research on those patients whose negative symptoms don't appear to be due to anxiety, depression, hallucinations, disorganization, and so on. In Europe, the usual term is predominant negative symptoms. And in the United States, it's more often referred to as primary or deficit schizophrenia. Now, in a clinic, they usually receive less attention than other outpatients. They kind of fade into the background a little bit, unfortunately, partly because their hallucinations, delusions, disorganization of speech and agitation are mild or absent. And these are things that clinicians typically worry about and routinely assess. Plus, by definition, as a group, they simply have less motivation, abolition. So they complain little. And in the United States, if they're placed in a group home, they tend to stay there. plus another factor for there being less, people pay less attention to them is there's an absence of established treatment. So clinicians are pessimistic about their prognosis and pessimistic about interventions. And all this is unfortunate because they have poorer function on average than do people who don't have primary negative symptoms. Next slide. So I'm going to show you some of the evidence of the importance of these primary negative symptoms for function. So patients in an outpatient clinic were rated for the presence or absence of primary negative symptoms. And it was a categorical rating, present or absent. And then five years later, they were assessed by other raters who were blind to the study hypothesis of function. And the primary secondary categorization that had been made five years earlier explained variance that was not accounted for by other symptoms. So what you see on the p-values is that after accounting for variance from negative symptoms broadly defined, for instance, on the SANS or the PANS, for the severity of hallucinations and delusions and of disorganized speech of demographic features and age of onset. Primary negative symptoms still had a significant relationship to horror function. Next symptom, sorry, next slide. So what about monotherapy, which is the design for the roloperidone studies? Well, antipsychotics decrease the number of relapses and hospitalizations in people with schizophrenia. So that raises questions about the use of roloperidone as a monotherapy, as it's not considered an antipsychotic. Now, as a group, antipsychotics are associated, as you with increased risk of weight gain and its consequences, including hypertension and diabetes, movement, and also risk of movement side effects, tardive dyskinesia, abnormal involuntary movements, Restlessness, which can really be miserable for someone and stiffness. They may feel sleepy during the day because of antipsychotics. And there was mentioned before of elevated prolactin, hyperprolactinemia. This is a hormone, a normal hormone that everybody has. But when it's elevated, it has certain problems, especially for women and other problems for men. and antipsychotics don't improve primary negative symptoms and can worsen secondary negative symptoms. And there's direct evidence on that latter part, that latter statement. Next slide. So people who have, are not, who stopped taking an antipsychotic have been studied for many years. and the broad conclusions are yes, they have more relapses. But if they have some contact or having in some contact with a clinic, serious consequences are rare. Also, some people are able to enter treatment because we'll accept that they will only take antipsychotics when they have increased symptoms. And patients also often have an increase in symptoms Such as nonspecific things like depression, anxiety, sleeping more before there's an increase in hallucinations and delusions and so on. What's interesting about this in part is that, in my experience, patients tend to have their own idiosyncratic warning signs. Some people consistently become anxious. Some people consistently simply become withdrawn. So they and their loved ones often notice these early changes in time to stop the worsening of psychotic symptoms. Next slide. Well, before I go on, let me just tie together a little bit more of a sense of who these folks are. The kind of thing that you might hear from family members is, you know, my son isn't worried about the FBI anymore. And he doesn't seem to be hearing things or seeing things anymore, but he stays in his room all the time. He says he's not depressed, he's sleeping okay, he's eating okay, but he's just not doing anything. And it doesn't seem to bother him that his life is really pretty boring. That's an example of things I've heard. So now I'm going to give evidence that patients who meet Minerva entry criteria simply have a low risk of relapse independently of treatment. I'm going to give you evidence from the Cady study again and from Minerva's CO3 and CO7 studies, the Phase IIb and the Phase III studies. Also data from a meta-analysis of relapse in patients who have been in studies of stopping antipsychotics. And also what is known about baseline symptoms will kind of take apart the symptom group, the symptoms that are used to define the Minerva entry criteria. We'll look at baseline symptoms and subsequent risk of relapse. Next slide. So Dr. Luthringer mentioned that there was a difference between patients in the KD study who did and did not meet the Minerva entry criteria. So the KD study had almost 1,500 schizophrenia patients who were recruited from 47 US sites, and they were then randomly assigned to one of Survive Antipsychotics and followed longitudinally. So what you see on the graph to the right is time to relapse. So 100% of patients at the beginning, those who met criteria and those who did not meet criteria, had not relapsed by definition. They were stable. And then what you see is that very quickly a difference appears. There are fewer who have remained without relapse. I'm sorry, there are more who have remained without relapse if they met the Minerva entry criteria. So their last data point, they had about 68% or 69% who continued not to have a relapse, whereas it is more around 58% or 59% in those who did not meet the criteria, and this difference was significant. So in this study that is not conducted by riloperidone that was published in 2005, You see that there's something about this group of patients that seems to confer a lower risk of relapse. Next slide. Now we're going to bring in data from a meta-analysis of drug discontinuation trials. And they were treated with placebo or an antipsychotic. And there were 9,000 patients in this meta-analysis. Well, what you see here are the data. The meta-analysis presented three months, up to three months, and then up to four or six months. That's why you have those two time points. What you see is that the two roloperidone studies that are up at the top, CO7, CO3, and the patients who were from the KD study, who met the Minerva entry criteria, but were on an antipsychotic, are all up at the top. not gonna push this too hard because not necessarily all the P values are significant, but you see that they are, they have lower relapses. And then if you compare those three studies from patients on placebo from a meta-analysis, there is a very big difference. And we're comparing with CO7 and CO3, we're comparing patients who were on monotherapy with Roliparadone, two patients who were drug-free and on placebo. So they were CO3, CO7, and the bottom graph, the black dashed line, none of them were on antipsychotics. The Katie study patients were. Next slide. Well, how about if you break it down into specific symptom groups? These are five studies from two repositories, the Iota and Vevely repository of clinical trials. Now, the Minerva entry criteria define a group. By definition, they have low positive symptoms and high negative symptoms. What you see on the chart is that, look at the top line. That is PAN's positive symptom factor. And compared, the greater the difference between patients with higher symptoms who are otherwise similar to other patients in the same studies, the greater the impact on risk of relapse. For positive symptoms, it increases. You have this stepwise increase the more they deviate from otherwise similar patients. Whereas with negative symptoms, the more negative symptoms they have. the less the relapse rate. So low positive, high negative symptom profiles, which is the patient group that we've been discussing, they are less likely to relapse. Given this, patients in Minerva's clinical studies should have a low risk of relapse. It would have been surprising if they hadn't. Next slide. and this is from essentially a similar finding from an Italian cohort of 24 university psychiatric clinics and mental health departments. It's a four-year follow-up study. And on the graph, what you see is four groups and the measurement there, as you can see on the axis, is PANS negative symptom factor score. So from seven to 16, all the way up to 28 to 48. And again, there's a stepwise decrease in risk of relapse over this four year period. The higher your negative symptoms, the less the relapse. Next slide. So what does this relapse evidence mean? Well, there's a consistently lower relapse risk in this population across decades, across national borders, across different studies, across various definitions of relapse, including hospitalization. So this provides evidence for not only the existence, but also the validity of this group of patients with this symptom profile. and for this group, Roloperidone has a reasonable risk benefit ratio. Finally, monotherapy with Roloperidone is an example of precision medicine. Next slide. So you have a pharmacological treatment that decreases negative symptoms. There's an important issue to keep in mind clinically for these patients. Many of these patients had had years of relative social isolation and poor function. And they may not have much confidence or much skill with regard to self-care relationships and employment. Despite that, in the 12-week intervals, all the Peridone patients have shown improvement in really the most widely used function scale, strongest function scale, the personal and social performance scale, which is a measure of function in the CO3 and CO7 studies. An important consequence, though, of successful treatment of their negative symptoms will be that they will be able to respond more to the evidence based psychosocial treatments, which, by the way, have pretty good effect sizes. So they should have the opportunity to continue to have further improvement. Next slide. And we are back to Dr. Luthringer.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Thank you so much, Brian, for all this important data. I think what Brian is really addressing is we are more and more working on this, but we are more and more characterizing this patient population. I think this is extremely important. When the drug will be available, the prescriber will understand which patients would benefit from this treatment. I think we are making a lot of progress, and I have to say that At Minerva, we have put together an outstanding SAB with these people who are speaking today, but with other persons who are really bringing a lot of their knowledge in order to really be ready to better explain how this treatment should be administered when it will be available to the patients. So what I will speak about just quickly as before handing over to Dr. Correll to Pistof is just some analysis we have done continuing to try to understand and to show the uniqueness of the effect of Roliparidone. And I will go through three different things. The first one is a Bayesian analysis we have done with our data. I will come to this in a second. and the other aspect is what we call the global statistical test and last but not least something which is very important is afterwards to compare how many patients are responding to our drug compared to placebo and this is obviously what usually the FDA is using they say okay the drug is improving I don't know positive symptoms and you have a 30% of the patients responding with treatment versus whatever percentage under placebo. So I will focus on these three things very quickly. So why do I show you the Bayesian analysis? So as you know, what you usually have to do is to have two studies, which we call frequentist analysis. You're analyzing the data in a frequentist way. And so in the case of Thank you very much. Thank you very much. were all known before we ran the study from the draft. And this is interesting enough, the FDA put out the guidance in January, 2026, in order to really explain how you could apply the variation analysis. So what we have done here is to, based on a very positive study, obviously the CESAR-3 study was a very positive study, we looked how much you have to borrow. So this is about borrowing, what you have learned from the previous study in order to make the C07 study a very successful study. And so what you can see very nicely for the primary efficacy endpoint, which is NSFS and PSP, what you have to borrow to really make the binational analysis highly positive is extremely limited. And clearly, I mean, we discussed this in length with Frank, Thank you very much. If you are applying Bayesian analysis, you can come to the conclusion very easily that rhodiperidone is working. So it's just another way to look to our data and to come to the conclusion that indeed rhodiperidone is working, not only on negative symptoms, but also on functioning. Global statistical analysis is an interesting one because global statistical analysis is, as you can see, it's to combine endpoints into a single test while correcting for correlations. So really, I think this is what's important. Usually what you're doing when you're analyzing data, you have your primary endpoint, you look into your secondary endpoint. And as you know, human beings, we are not completely objective. So this is a way to really demonstrate that indeed, I mean, using a very robust statistical approach, that indeed, Improving negative symptoms is translating into an improvement of functioning. So obviously, when you're doing GST, you have to combine something which makes sense. And here is exactly what we did in the two studies, primary efficacy endpoint and sole key secondary endpoint. What you can see very nicely is that for the CSRS3 study, you have a very, very high p-value in the GST-approved, so basically combining negative symptoms and functioning. look to the caesarocellin study, again, highly, highly significant. And what matters at the end of the day, indeed, is that these patients are functioning better, as we heard from Dr. Strauss. So clearly, I think this is a very nice demonstration that with an objective statistical tool, we are demonstrating that the two things are really correlated, not correlated, that negative symptoms are producing a very strong functional improvement. And when you're integrating, obviously, the two studies, at the bottom line, the things are staying extremely significant. So I think it's a very objective way to reemphasize what Dr. Strauss was saying, that I think the uniqueness of Roliparidone, it is on one hand improving primary negative symptoms, but it is also transforming into a functional improvement, which is, best of my knowledge, has never been really demonstrated. Now coming to but usually the agency is looking at this and this is what we call the responder analysis. So on the complete left side, this is a classical responder analysis. So you're looking to the primary efficacy endpoint, you're looking to the patients who are improving more than 20% during the course of the treatment and you're comparing this between the placebo group and your drug. What you can see very nicely here is that the patients are treated with Roliperidone 64 mg. It's around 38%, whereas for the placebo group, you are at around 22%. Usually also, and I'm speaking under the control of Frank, when you're going above 30% of responders, I think this starts to speak positively for your study. We wanted to go further down the road in order to better understand the difference between rhodoperidone and placebo. And so what we did, and this is the middle analysis, what we did, basically, Jonathan, who is here in the room, did. We did an analysis where we were anchoring the primary efficacy endpoint, so negative symptoms, NSFS. We were anchoring this to CGIS. It is very well described in the literature that one point improvement or more of the CJS is clinically meaningful. This is really telling you that something good is going on in terms of functional improvement of the patient. And look again, definitely roniparidone 64mg is much better than when you are treating your patients with placebo. Last but not least, we wanted to focus on functioning. And we did this analysis using not as a primary endpoint negative symptoms, but PSP functioning. And this is on the right side of the graphs on the right side. What is known from the literature, and I think Dr. Nashrala published this in length, is that when you have an improvement of more than seven points of the total score of PSP, This is really clinically meaningful. What we did here, because our recent publication showing that, I mean, if you're going to 10 points or more improvement Not only the patients will function better, but I mean, the likelihood that they might relapse is also reduced. So just to continue to better understand our data. But so when you're looking to these results, which is very challenging, yes, to reach 10 points, you see again that definitely Rhodiparidone 64mg is doing a much better job than PSP. To put this into the context, you see that another way to look to this data is to look to the number needed to treat. So how many patients do you need in the treated group to be better than the placebo group? And you see that the numbers for these three types of analysis are seven, eight, and nine patients. It might look a lot, but when you're putting this in the context and you're looking at the number of patients, this is at the bottom right, The number of patients you need for antipsychotics and for antidepressants, we are exactly at the range. So just to say that it's always very difficult to say that all this is clinically meaningful because I think it's too early because this is the first drug really moving the needle on negative symptoms. But I think all this data really demonstrating that there is a real benefit for the patients who are treated with rhodoperidone compared to placebo. I have a pleasure to hand over to Christoph Korell, who is making some emails. But Christoph, you have to speak now. Thank you, Christoph.
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
Great. Thanks so much, Remy. Thank you all for being here today. I hope this is on. Yes. So my name is Christoph Borrell. I'm professor of psychiatry, molecular medicine at the Zucker School of Medicine at Hofstra Norgwell, where I've been for the last 29 years. And I'm also professor and chair of the Department of Child and Adolescent Psychiatry at the Charité University in Berlin, where I've been for the last eight years. My work for the last 30 years has focused on clinical work and research in people with mood disorders and psychosis. And we talked last night about regret, and basically I have one professional regret. And when I started medicine, I was a little naive. I thought I could cure and understand schizophrenia. I now understand this is out of reach. But I have one personal regret, and that is that during my work, and work of many others, we have not yet found a treatment for negative and cognitive symptoms in people with schizophrenia, the two drivers of disability. And that's why we're here today, to change that regret. So let's talk about the negative symptoms, but also where Roloperidone, if and when it's being approved for negative symptoms, can go. Because these symptoms are not owned by schizophrenia. Our brain has multiple ways of expressing something that is positive, but also something that's missing. And this missingness cuts across multiple disorders. So I see a lot of opportunity for Roloperidone to help patients with other disorders where there's a lot of disability. Let's briefly revisit what Greg Strauss has been talking about, the negative symptoms. The way we currently narrowly define them for schizophrenia They have to do with two dimensions. One is expressive, where we understand what the patient is maybe feeling and thinking. It's very important for social interaction. That has to do with blunting of fact and also aloja, not talking much. Patients have a hard time connecting with other people if other people can't read them, if they can't express themselves. What is even more relevant for the functionality, though, is the intrinsic experience of life. And that has to do with anhedonia, not being able to experience pleasure, but then also the expression of that motivation on the social level or other things. Asociality is central. People just sit on the couch, as we've heard. They're not interested in other people. And families beg us to bring their son and daughter back. They feel their children, their loved ones have checked out. They're just physically there and not much more. And this abolition cuts across everything. Families notice when something changes. They just want their loved one to pick up the newspaper again and show a sign of light and interest in life. That's what we're here for. We need to change that. There are different ways of cutting the pie of negative symptoms. Some have even some cognitive aspects in there because Professor Strauss also mentioned that there's this interaction between cognition and negative symptoms. You can only use your cognitive abilities when you're motivated to do so. but when we looked at multiple studies the frequency of different dimensions of negative symptoms might be different based on the patient population we're looking at but within each study we could see that the blue is more frequent than the red is more frequent than the green so that means we have a lot of We have a lot of social amotivation, no matter what the study is. My apologies, it has to do with the study. But you see that within the red, within the blue and within the green, we have more social amotivation, then we have diminished expression and then inattention, elogia. So this social aspect, not being able to motivate yourself to do things is crucial that we need to address. because negative symptoms have multiple pathways into eroding people's lives, eroding their social interactions, eroding their aspirations for job and also for work. and Freud said the two things that are relevant in life is work and love and those are the two things that are undermined by negative symptoms even more so than by positive symptoms which we can now treat and as you've seen in the subtype of patients that have Little Residual Positive Symptoms, that is not the issue anymore. So this type of precision psychiatry that also Brian Patrick was talking about is unique. We don't have any psychiatric treatment right now that has focused on a biological and clinical subgroup that is relevant. and that gives us much higher likelihood of success rather than blasting patients with one medication to treatment of patients that have very heterogeneous results and also underpinnings. Again to just highlight the interaction between cognition and negative symptoms. Cognition gives you the ability to do something. It's your capacity. But without then doing something about it, you're just keeping your capacity floating freely around. You need to have performance. Functional performance has to do with executing this. And the execution of your capacity has to do with motivation and seeing also value in doing it. and the value has to do with hedonic drive. I can anticipate that things are going to be good. I can enjoy them and that then gives us reinforcing behaviors. We know that people with negative symptoms also have high cost that accumulates. So here, payers should be very interested in that. We know the interest by the FDA is great because you don't even need to have an extra outcome of functionality. This is a given, not so much with cognition. With cognition, we need extra measurement of outcomes on the functional side. But since negative symptoms and functioning are so tightly intertwined, that is not needed. Now, we've seen with the data for luparidone that PSP was really moving even stronger than the negative symptoms. So we see an agglomeration of the effect on what patients want, what families want, and what regulators are interested in. Now I mentioned that I'm also a child psychiatrist and I became a child psychiatrist because I wanted to prevent the illness and That means we're looking at the so-called prodromal phase. It's the clinical high-risk phase where patients don't yet have positive symptoms, but this is loaded with negative symptoms. It's loaded with cognitive symptoms. So while we still need to collect data on that, there is at least a prospect that by treating the negative symptoms early in the illness, we might be able to avert it. There are other areas in the brain that come online in order to compensate for that. Now, this is future music. One would have to look into this, but it's obviously very, very compelling. And even if patients don't yet have the real risk for psychosis, treating negative symptoms early that are independent of depression will help them even at that stage to function better. Now, this is a slide that I got from Greg Strauss, like the last one and the next two ones, which really has a lot of text on there. And this should dizzy you because that's the purpose of this. How dizzying is it that the negative symptoms that were defined and we've always been talking about in the context of schizophrenia are actually might occur in 18 other conditions. And that has to do with the fact that what we call negative symptoms, this terminology, when you use some other words that have been used in other conditions, actually it converges on the same thing. has to do with lack of motivation and willpower, has to do with apathy, not being able to get yourself to experience something or express yourself, and it has to do with anhedonia, not enjoying things. And these aspects really cut across multiple domains. The question then is obviously, where would one put one's emphasis the most? And we'll get there in a minute. First, some more data that Greg Sprouse also put together just to show you that the so-called negative symptoms, which is a group term for problems that is there is an absence of things in the brain and in people's lives, cut across not only schizophrenia, but also major depressive disorder. The ultra high risk syndrome, which I just mentioned, the risk syndrome for psychosis, bipolar disorder, and it's much higher than in healthy controls. Now, we could say that some adolescents have a little bit of negative symptoms. They have all the capacity and just sit on the couch. That's a prodrome to adulthood, but obviously we need to motivate everyone to do better and express themselves. Because especially during early phases of development, when you have learned that you're not able to do certain things, that people don't read your emotions, that you're not connecting, that becomes part of your persona. You don't even expect this to change. You're not really motivated to do things about it because there's no reinforcement. So this reinforcement needs to come by lighting the bulb up again and getting patients back into life. And here you see the comparison of the so-called negative symptom domain compared to people in the and you can see that it really cuts across multiple of these disorders and that there's a big problem with anhedonia and able vision. So putting all of this together, where could Roluparidone fit in the clinical treatment paradigm? Thank you very much. showing significant improvement of negative symptoms without needing the dampening on the brain of the dopamine-blocking medication. That is unique. No other company has really tried that. And it's bold, but I think it's possible when you do use this precision psychiatry approach, giving the right treatment for the right patients. Now, what other patients might be right patients? Well, schizophrenia and schizoaffective disorder for the right are very, very are closely related. They are almost siblings because you still have all of the schizophrenia side, but there are symptoms of mania or depression. These patients also frequently have negative symptoms. On the left-hand side, major depressive disorder I think is a number one target because we have patients where the depression is treated. They're not sad anymore, but there's residual anhedonia, apathy, and also the lack of ability to enjoy themselves and connect back with life. They're sitting and they are not sad anymore but they are blank and there's a lot of emptiness. So hopefully for these residual symptom patients in a very frequent disorder like MDD, Roloperidone could play a major role. We're all aging. I have to break the news to you. but also the population is aging and we will have more and more Alzheimer's disease patients. You know that. And we also have two types of Alzheimer's that is really problematic for families and societies. One is obviously where there's the too muchness of psychosis and agitation and some companies are going that route. But what we're really Not focusing enough on is the apathetic subtype of Alzheimer's disease, where basically patients are disappearing from their families. They're just sitting there and they're not interacting. And that is so painful that you're losing your loved one this way. You want to reach them and they're like behind a milk glass. This apathetic type of Alzheimer's disease has a very high likelihood to also respond to roboperidone. Now, looking at Parkinson's disease, where there is a lack of juice in the brain, there's too little dopamine, there's also a lot of depression, but apathy. So here, I think it's a high likelihood that this could be treated. Similarly, in another neurological disease, multiple sclerosis, where there is a shutting down of certain neurocircuits that need to be lit up again in order to make patients more interact and enjoy their life. Now, COVID has brought us a lot of patients who have long COVID now that somehow can't get back into life, can't light the bulb again in their life. And they are often just sitting around, lying around and have checked out. So this long COVID post-viral syndrome that we don't fully understand yet what happens in the brain, may also respond to Roloperidone. And very much related to that is the myalgic encephalitis or chronic fatigue syndrome, which has been around for many, many years where we don't have anything approved to treat this kind of illness. And then finally, traumatic brain injury is another disruption of the brain that hopefully A treatment like rhodoperidone that treats apathy and anhedonia and amotivation in people with schizophrenia where the hardware is impaired. Here we have hardware impairment after a traumatic event and it's also a real target. And then finally, let's finish up again with neurodevelopment. What about autism spectrum disorders where we have also, like with Alzheimer's, a too muchness of aggression? and Agitation, but we also have this lack of social interaction where we have this checking out and just being in your own world. You may know that Leuler, who coined the term schizophrenia, actually felt that one of the main features was autism for people with schizophrenia, meaning being in their own world, being shut off from others. So here I think Rolo Peridon again would have a path forward. And since there needs to be a pediatric plan, That would be something I think to actually study rather than schizophrenia, which is much rarer in children and adolescents. And other companies have done that, that they actually use this for agitation and aggression as their primary autism, as their primary target for fulfilling the pediatric plan. So I thank you for the opportunity to talk about this transdiagnostic opportunity for Roloperidone once and if it's approved for schizophrenia and negative symptoms. Thank you very much.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Thank you, Christian. Incredible presentation. Thank you. And I think very importantly, you see how important it is to bring Roloperidone to patients and afterwards, It might open to a lot of other disorders where there is a huge medical need. So I think it's our duty here to come to this. Let me just go back to the numbers because everybody likes numbers. This is just to give you a flavor about what is the opportunity, when we will have the data in hand of the C19 study. So this is really focusing on the patient population we are currently targeting. And these are some data. So you know that the prevalence of schizophrenia is, depending on the studies, one person, 1.2 percent. And so this represents, and here I'm focusing on the US only, it's around 3.4 million in the US who are definitely suffering from schizophrenia. Interestingly enough, the number of patients who are treated or seen by the medical system are not from all the patients, but I mean, it's nevertheless 2.2 million people who are seen by the medical system in the US, so a very large population. Afterwards, when you apply our criteria somehow, yes, so patients who have negative symptoms, this is going down to 60% of this population who are these patients who are seen by the medical system. And so you end up with 1.3 million people. And when you're going with patients who are stable, because this is what we are aiming for here, what our studies are recruiting, you know, you end up with around 900,000 patients who might benefit from Brodyperidone In the US only. Maybe people who have seen our previous data say they have increased the number. No, we have not increased the number. What has changed since the last review we did is that the number of patients seen by the medical system has increased. In our last analysis, it was half of the patients. Here it is more than half of the patients, which is explaining why. The difference here is just to be clear that we are not emphasizing or inflating the numbers. It is just because more patients are seen by the medical system. Now, the same is true for the overall market for schizophrenia. It has also increased. It is now at around 7 billion. On negative symptoms, there is definitely no dollars coming because there is no approved drug at the moment. And when you apply this to our patient population by using the criteria I was showing you before, this is an opportunity for the first indication, which are negative symptoms in patients with schizophrenia. You're speaking about an opportunity of more than $2 billion. So before opening the Q&A, hopefully you have a lot of questions because I think what we're doing here is so exciting. And when I hear my colleagues speaking about it, how important it is, it gives, I think, to the complete Minerva team the energy to move forward and to continue to work. But so I think Minerva is the right conference here. We have definitely here the right pharmacology and the right mechanism of action. It is, I think, the only drug today who shows really clinically relevant improvements. We are really showing that, I mean, we're able to improve primary negative symptoms. And, you know, after presentation like the one from Christoph, I think you're all convinced that, I mean, there is a label expansion which is possible with this drug. Importantly, and we discussed this, what I think we brought to the table, even broader than Minerva to the medical and scientific community, is to think about the fact that patients with a diagnostic of schizophrenia are heterogeneous. And I think we are able to really come up with a clinically relevant population who has really these impairing negative symptoms. and with a low risk of relapse. So I think this is coming to the notion of precision medicine, but this is extremely important. And I think this is not important only for schizophrenia. We can speak about depression, it's exactly the same or other disorders. But I think this is a second pillar of what we're doing here. Now we are understanding more and more data, more and more the patient and more and more why these patients are different in terms of are reacting to the drug in terms of negative symptoms, but also why they are not relapsing. Something very important, obviously, we need to have a positive C19 study. The team is completely focused on this, but I think it's about execution. It's not about the fact that you have a drug or not. So because when you're looking to the two previous studies, we definitely show a very good discrimination between placebo and treatment for negative symptoms It took us time. I know that some of you were questioning me often. Why did you not start your study immediately after the feedback from the FDA? I think it was necessary that we opened the dialogues, that we had these interactions. And as I said at the beginning, we really got very, very good advice in order to come up with a C19 study. and we learned all from the two previous studies that we have implemented and it's long to go through it, all implemented in order to really magnify the effect of Roliparidone, keeping the placebo effect under control and definitely coming up with a positive study. It's also the right moment because I think the space is really moving. Patients are more aware about negative symptoms. The scientific community is working on it. The medical community is working on it. It's important, and I wanted to highlight this very strongly. I mean, we are backed by world-class investors, which is, as you know, without having these people supporting us, nothing is possible, unfortunately, in drug development. So thank you to all the investors who are supporting us. And I think when you think about the opportunity, There is an opportunity to have a big readout coming during the course of next year, hopefully confirming that the drug is working on negative symptoms and transforming into functional improvement. It's time to hand over to Q&A. So maybe Christophe and Greg and Frank, maybe you can sit. And we have Brian somewhere. So can we see Brian?
Brian Kirkpatrick
Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences
I can see you. We're good.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Okay.
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
Please. Mike is coming.
John
Representing Andrew Tsai, Jefferies
So this is John here for Andrew Tsai from Jefferies. Just as we think about the real world use case for roluperidone, I can imagine physicians would be incentivized to take patients off of antipsychotics, which come with a lot of safety liabilities. But then I can also imagine there is hesitancy to take patients that are well controlled on their positive symptoms as well. So as we think about discontinuing an antipsychotic, and then cross-tie trading or even using adjunctively, like where do you think the ultimate real world use case will kind of skew towards?
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Maybe we can start with Brian. Ah, you're on mute.
Brian Kirkpatrick
Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences
My apologies. I suspect that both will happen. Some people will start monotherapy, some people will continue an antipsychotic. And I think the company would then have the option of providing some education for those people if a lot of people continue an antipsychotic, might be able to present them with an educational is an educational effort that perhaps includes talking about tapering off the antipsychotic slowly. I think Christoph had some thoughts about that yesterday. He might want to add.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Yeah, Christoph, please.
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
Yeah, so I do believe that Clinicians will be wary of the worsening positive symptoms. So there will be first an adjunctive treatment. And then since patients always ask us to lower the dose or stop that treatment over months, would we, I think, then very slowly go down so that we could catch them should these patients not be guarded or protected against relapse and wouldn't have a bad outcome? But I also, and many patients I think will continue this and finish the frost titration. But I think that there are two other groups that we haven't really focused on where this will be used the most and fastest. about 50% of patients are non-adherent themselves and there are those that are not on an antipsychotic anymore but they still have negative symptoms and that's where families might bring them in where patients are still in contact and they could be started safely and maybe the relapse prevention with Roloperidone's effect could then be stronger and I think also first episode patients first episode patients that get schizophrenia treatments The clinicians are often very unclear. Will they have a second relapse or not? And negative symptoms are very common. And patients, families want us to try at least once without. And that's the perfect population where we at the moment have nothing to offer. We say, I think 80% chance that you will have a relapse. So we need to continue. But what if I'm in the 20%? So those patients that are often even based on guidelines, given at least one chance, that's the perfect treatment for all of them.
Frank Sasinowski
Regulatory Counsel and Former FDA Official
Let me say this, and by the way, I'm Frank Sassanowski, the guy Remy kept referring to as Frank. No, no, no. I left the FDA 39 years ago as Deputy Director of Health Policy, Commissioner's Office. 39 years, I was in one law firm helping people get new drugs through the FDA pre-approval call. So I've helped over 200 new chemical entities get approved, including Rizzolte, Clobamphi, and Capita. in the world of schizophrenia. So let me say this, that FDA, I'm all about FDA. You've been hearing about science, now a little bit about marketing. I have a myopia. I only think about FDA. That's all I think about. And with respect to FDA and getting to market, the FDA cares about making sure that it has the right evidence for which it can label so that doctors have adequate directions for use. Beyond that, so that they will approve it, the FDA, if the phase A results come in next year and they're positive, the drug will get approved. It'll be approved because it's effective. The questions about relapse are a safety question. Safety questions, the FDA has a lot of tools in its toolkit to deal with safety issues, including labeling. So the relapse issue, it's not a big issue. And in fact, at our September meeting with the FDA, the FDA said, yeah, we agree with you, Remy. We agree with Minerva. Your relapse rate is likely lower than it is in general because of the patients that you're going after. But what I want to get to is your question about label. The FDA only cares about labeling it on the evidence that it's provided with. So it would be provided just for the patients that were studied in CO3, CO7, C19. The rest of it, which you're talking about, like Christoph's talking about, first episode and these other things, and what you were talking about, that the FDA says is not on our shoulders. It's not in our task. We are not responsible for What people do off-label is up to the medical community. We only are empiricists. We just deal with data. So I just want to make sure that you understand there's a difference between what the FDA will approve you for. and which I think will happen if the Phase A results, 12-week results are positive. And in fact, in our discussions with the FDA, what's fascinating to me is that in this discussion today, as a regulator, there was no discussion about whether or not this drug works. There was no discussion of that in September. with the FDA. The CRL, the complete response letter, which we got in February, 2024, which says, we're not approving you on the basis of CO3 and CO7. The first issue was substantial evidence of effectiveness. The most important issue to the FDA was, does it really work? Does it provide benefit? And yet, where are we today? Nobody's even talking about it. Not even the FDA much, as long as we're in September, which means that to me, as a guy who knows nothing but FDA, This drug is getting approved. Those phase A results in 12 weeks come in, and FDA almost has no doubt that they're going to come in positive.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Thank you, Frank. But I think it's very important to make this distinction. So really, thank you, Frank. And by the way, the update has not told me Remy. I'm not yet at this stage. But... A small thing I would like to add. So we already have a lot of data because obviously we are very well aware that this drug might be a medicine on top of something else, antipsychotic, but it can be also on top of another treatment, as you have heard. I mean, this will be also maybe prescribed We have already a study we have performed, which is called the C18 study, where we have co-administered olanzapine with our drug, just to demonstrate that it is possible. I'm not speaking about efficacy, just that it is safe. I think it is a small study we have done, but definitely it is safe. and we have a lot of preclinical data showing that the risk of DDI is extremely limited with our drug. But again, this will be taken care of during the labeling. What I wanted also to mention, because this was often a comment I received from a lot of people, why are you not doing like everybody, put this on top of an adipocyte particle? And so we decided, and I was stubborn, you know, and I got a lot of criticism. I said, no, let's first focus on this patient population we have discussed today to demonstrate that we are improving the primary negative symptoms. And afterwards, we move to something else. But think one second about developing it on top of a non-deep psychotic. Which dose should we use of the antipsychotic? What is the level of binding of dopamine in the brain we should have in order to co-administer the drug? So I think this is something which is a little bit more sophisticated than just to say, put it on top of an antipsychotic and hope for the best. So just to mention that you're thinking about it, you're conscious about it, and you're working on it.
Frank Sasinowski
Regulatory Counsel and Former FDA Official
Let me say this about that. Slide 11 that you saw on the slide... quoted Stephen Marder at UCLA for saying that a monotherapy is the best design to look at a treatment for primary negative symptoms. Stephen Marder at UCLA was the person for whom Mike Davis, who is currently the head of the Center for Drugs at the FDA, Mike Davis worked under Stephen Marder at UCLA. So, and Mike Davis then is a psychiatrist who's keenly interested in schizophrenia, studying under Stephen Marder. And When Mike Davis left the FDA temporarily, he was at the FDA, he left for a little while to go to a nonprofit called USONA to help work on psychedelics for treating PTSD. When he left, he called me, he said, Frank, the best work I saw at FDA when I was at FDA was from you. I'm now the CMO at USONA, would you represent me? I said, sure, Mike, I'll do that. So Mike now is back at the FDA, a psychiatrist, head of the Center for Drugs. whose profession was built on looking at schizophrenia and with people like Stephen Martyr who focus on negative symptoms. Guess what happens when you have somebody like me who knows people like that who are interested in this issue? It means that we have an ability to invoke, escalate these kind of reviews so that if we have any hiccups, In our review, when these phase A results come in, we have many ways in to talk to people who can help with the decisions to be made.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Thank you, Frank. So next question, because I think if we take as long for each question, I think we will be here until four o'clock. I can go off. No, no, it wasn't a criticism. Next question, please. Yeah, Michael.
Frank Sasinowski
Regulatory Counsel and Former FDA Official
And do we have any from the audience?
Michael Kaiserman
LifeSci Capital
Let's go through the room and that's it. Sure. Michael Kaiserman, LifeSite Capital. Maybe two questions. One is when you sort of look at this patient population and think about kind of quality of life, obviously PSP is measuring a lot of that function on a daily basis, but how are you guys thinking of capturing the quality of life benefit that Roloperidone really offers for these patients? And that will be obviously very important for the far more economic argument as you guys are going to go to payers and really think through that. So I'd love to get some more thoughts around that.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
I would like to take this question.
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
I can. So basically, there is no dedicated quality of life scale in the study at the moment because the more rarefied the assessments, the more likely you'll be placebo. But we have clear data that functioning improvement really translates into quality of life. So that could be triangulation studies looking at other studies where When PSP improves and they did have a quality of life measure, that that also improved. So I think that's less in question and functionality is measurable and observable. So I think that has more traction even with payers than quality of life, which is a very subjective and neither here nor there kind of an outcome. But maybe Greg, what's your opinion?
Gregory Strauss
Professor of Psychology and Neuroscience, University of Georgia
Yeah, I definitely agree. I can also add there are some of the items, some of the scales that are being administered that get at the subjective experience of the patient. So how much, in addition to what they're doing, how much do they want things to change, how important is that? How connected do they feel with other people, not just how much are they actually engaging in those interactions? And that subjective portion is very important for quality.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Brian, do you want to add something?
Brian Kirkpatrick
Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences
Well, you may not like what I want to add. My thought was, how difficult would it be to ask the patients at the end of the study if their quality of life has improved and look at it for placebo versus drug?
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
So you're spot on because we have this kind of question at the end of our new study. So definitely we have it and we will document it. So hopefully the two things will match together.
Frank Sasinowski
Regulatory Counsel and Former FDA Official
For some reason that I don't quite understand, FDA is fascinated with what we call exit interviews in all studies across all disciplines. And I say I'm perplexed by it because the FDA really does dig in to those exit interviews, the very thing that Brian was asking and the very thing that's being done in study 19. The FDA, the Associate Director of the Office of Neuroscience, Dr. Michelle Campbell, is a pharmacometrician. And she likes to look to see the correlation between what those exit interviews say about how people are changing their activities of daily life and look at their scores on instruments like PSP or the PANS or the NSFS. So there's a great regulatory interest and looking at that. So it was a very good question. I don't know if you knew how relevant your question was, but it was a great question.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Michael is an open book, so I probably knew him. Any other questions, please? If not, is there a question from... Ah, Doug.
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
Wait for the mic. It's coming.
Douglas Tsao
Analyst, H.C. Wainwright
Doug Sal from HC Wainwright. So I'm just curious how... Given the introduction of new mechanisms of late, as well as over the years there have been some drugs that have tried to make claims around treating negative symptoms, although have never been able to get labeling. I'm just curious from your perspective, like a product like Voilar, how effective they are, and even some of the newer agents that have been approved, how has that affected the... The pervasiveness of negative symptoms or their severity, if you will, and the need for both primary as well as secondary negative symptoms.
Gregory Strauss
Professor of Psychology and Neuroscience, University of Georgia
Do you want to go first? I was going to say, I think it's becoming clear that drugs that have shown an improvement on negative symptoms measure very broadly. they also concurrently are having improvements in these other domains, positive, depression, anxiety, disorganization, et cetera. And the real question is, is there a temporal effect? Are those improvements lagged in producing the improvements in negative symptoms? I'm not aware of companies doing these specific analysis. That's one way to test it. But the assumption is because they're occurring concurrently, that there are secondary effects occurring. And I think it's a very logical assumption. So to date, no drug has really been thought to cross that threshold. That's been an actual change in primary negative symptoms. The other issue is the enrollment criteria. Most studies have had a very broad enrollment criteria. They've not enriched for the primary phenotype as Minerva has. And that over-inclusion results in a high amount of these secondary phenotype patients who are driving the improvement in negative symptoms due to these secondary source improvements in positive symptoms of depression and anxiety.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
I think you're addressing a very important point because if you take the example of Rayla, when you're comparing Rayla to Risperidone, Obviously, you will win because Risperdal is known to be very sedative, to have a lot of side effects. So I think the study design and the patient population is important. Just speaking about depression, we have kept in our study the level of depression. And this is very important because I always remember the first time Brian came, he said, I don't believe your data because you have probably no control for mood, yes? And indeed, we control for mood, yes? And here we have Brian Steele supporting us. But I think all these kind of things are very important. They are not seen when you're looking to a study design, but this is exactly what we are implementing in our study in order to really being able to claim that there is an effect on primary negative symptoms. We have even taken a patent on mood. I think the drug is doing something on mood. But I mean, to really demonstrate what we wanted to demonstrate, you have to come up with this kind of criteria. And I agree. Often it is much too large. And to claim that, I mean, you have an improvement is a little bit a conclusion which is too...
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
You also mentioned how the landscape might change with some of the agents that are coming. Most likely, implicitly, you talked about the muscarinic modulators. The muscarinic agents have, especially M1 and M4, some reason to believe that they may help cognition. They're not good data at the moment at all, that independent of improvement of positive symptoms, they can improve negative symptoms. The partial agonists you mentioned, that's a riprazine, but also aripiprazole, rectiprazole, they lack some of the secondary negative symptoms due to over sedation and B2 blockade, but we don't have a solution for these residual through primary negative symptoms. So they are still out in the open. And I don't think that any agent at the moment in the making really has a very strong prospect, except maybe for LB1 or 2. But there is no study ongoing at the moment, which is N-methylated amisulcride. But that will be a small subgroup of patients, whereas the muscarinics, they are used mostly in combination. and with the combination, it's hard to break through any of the D2 blockade. So I think Rural Peridot at the moment would be the sole potential option that I see that's viable. Frank?
Frank Sasinowski
Regulatory Counsel and Former FDA Official
What I was going to say is that if you went back to that February 2024 complete responsibility, but the FDA said no when we first tried to get marketing approvals, You'll see that one of their comments, I think it was the third comment down, it talked about how difficult it is if you had a drug on top of an antipsychotic. Because the antipsychotic, as Greg explained, the antipsychotic can either induce secondary negative symptoms or can treat secondary negative symptoms. So if you're just looking broadly at negative symptoms, like I helped in the approval of Coventry, and I know when they they came out with their analysis they said we treat secondary you know we treat negative symptoms because if you look at the pans you look at the negative symptom domains you would see they had an improvement but as Greg was explaining and as FDA said in our complete response letter but you can't tell where that's coming from and so I think that you need it's just like Stephen Martyr on slide 11 said the and that's why ISCTM you know has endorsed this idea that if you're going to look at primary negative symptoms, you have to look at a monotherapy study design.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Any other questions before maybe questions coming from people who are connected?
Unknown
Webcast Q&A Moderator
We have several questions that have come in through the webcast in written form, a lot of which are good continuation of what we've just been discussing here, but this one is directed to Dr. Kirkpatrick. and if a treatment for negative symptoms like roloperidone has more of an effect on function than the treatments for the positive symptoms, wouldn't you expect it to have a stronger effect size on the PSP scale than say the antipsychotics in the populations that they've studied?
Brian Kirkpatrick
Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences
Well, just... Not necessarily. Keep in mind the comments I was making about the history of these patients. They have a long history of not being successful in a number of areas as a group. And overcoming that, partly through encouragement and better experience and treatment, it would be really important. So antipsychotics work relatively quickly. Yeah. Yeah.
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
And just one more point, the effect size for PSP with the antipsychotics used in the acute studies, again, suffering from the pseudospecificity, because your functioning goes up when you're not withdrawn and anxious that people might hurt you. So you can't compare that effect size versus the residual negative symptoms.
Unknown
Webcast Q&A Moderator
about the possible effect in early prodromal symptoms was interesting and were you trying to imply that it could alter the future disease progression? And then secondarily it asks, And then among the nine indications that you showed on slide 50, you said MDD would be your number one choice. But would you envision this being used as monotherapy, adjunctive therapy, or in the treatment resistance depression setting? How best to show the effect in a clinical trial setting in MDD?
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
Yeah, so I mentioned with the clinical high-risk syndrome that this is really something to try to figure out. These patients are not so easy to identify while they're on the path to maybe psychosis or other disorders. And it's a testable hypothesis whether intervening with the mechanisms that underlie negative symptoms, one could stop the progression into other illnesses. I think we don't know enough about it, but... that could be a phase four question. Wouldn't be my first question, but it's certainly something very intriguing. Now for the antidepressant side, there we don't have dopamine blockade that could counter some of the rhodoperidone effect. So I think here one could try the combination treatment in patients who have needed antidepressants in the past and have residual symptoms, but there are others that might have residual symptoms even though they're coming off the antidepressant. and have still some cognition, insomnia and negative anhedonia type of symptoms. And that would be a separate group that one could try as monotherapy.
Gregory Strauss
Professor of Psychology and Neuroscience, University of Georgia
I can add a comment too about the clinical high risk group. So one of the really important things to know is that population, it's very prevalent for them to have negative symptoms, over three quarters. I think the published numbers are 82% will have negative symptoms in the clinical range. Importantly, these are not attenuated. They're not attenuated like their positive symptoms are. Their negative symptoms are as severe as people with schizophrenia. So that's point number one. Point number two is when they occur, even if they don't convert, meaning even if these at-risk youth never develop full psychotic disorder, they continue to have poor functioning. Whether their positive symptoms improve, whether they develop depression, anxiety, etc., they continue to have poor functioning. So this drug could be very helpful. For many people in this clinical high-risk syndrome group, treating their negative symptoms is going to improve functioning. These kids need clinical attention and help regardless of whether they convert. They're a clinical target that should be tackled.
Brian Kirkpatrick
Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences
And if you're a teenager, it's better if you're having some social success and learning how to maneuver in the adult world. did not. So if you give them some success by helping them with the negative symptoms, that can only help them in later life.
Unknown
Webcast Q&A Moderator
I agree. I probably have time for one more question that came in, unless there's any more in the room or ask this one. This is directed for all three of the speakers. and it's asking in everyday clinical practice and how good are clinicians in their initial diagnosis and workup in identifying the same kind of symptoms that are specific in this clinical trial for roloperidone or is it going to involve a lot more education so that they can diagnose the patients that are most likely to benefit from this?
Brian Kirkpatrick
Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences
They routinely assess positive symptoms and negative symptoms. The finer points of negative symptoms, I think, are usually not well taught. And they are going to be a little fuzzy on that. But I think it's one of these things where they say, well, I can't define it, but I know it when I see it. It would be helpful if we could teach more people to some of the finer points in the assessment of negative symptoms. On the other hand, I think that actually the drug itself will end up teaching them a great deal.
Unknown
Webcast Q&A Moderator
Great. Christoph?
Gregory Strauss
Professor of Psychology and Neuroscience, University of Georgia
Yeah, I definitely agree with that. I think clinicians are almost always very adept at assessing depression, anxiety, disorganization, understanding when there are antipsychotic-induced effects. So they're implicitly aware of these factors that are common secondary sources. Whether they label them that or not may not matter that much. I think that they'll be very good at knowing when they're present. And by default, knowing when they're absent as well, which will define the treatment. So I think in routine clinical practice, they are very adept at making this determination. It's just really formalizing.
Christoph U. Correll
Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell and Charité University Berlin
I agree that clinicians know about positive and negative symptoms. That's the basic teaching, but it's more like a qualitative, dimensional way. It will be very helpful for Minerva to develop some tools that accompany them in order to make people much more focused on it because you watch for what you know and you recognize what you can measure. It has to be very simple, just absent, mild, or more than that. But that's doable. And we've had also examples for that, like the type in going into many billions of dollars for bipolar depression when there was a tear off sheet and patients filled out something, how they felt and what symptoms they had. So having tools available sharpens the eye and brings out that there is a new treatment for a condition that we currently couldn't treat. So education will be crucial to that.
Frank Sasinowski
Regulatory Counsel and Former FDA Official
One thing I want to say on that from a regulatory perspective, because that's all I can bring, that what strikes me is that if the question was saying, can people trained in the field identify these patients that are the patient population, that an indicator to me as a kind of a regulatory maven, you know, an indicator to me is that the speed with which 03, 07, and 019 enrolled, If you needed to go out and have a whole campaign teach physicians how to identify these patients, then it would have taken longer than a normal anti-psychotic study in schizophrenia to enroll. The pace at which these studies enrolled was the same. It's as though physicians understood. It's like Brian said, it's like justice as the lawyer in the room, just as Potter Stewart said about pornography, I know it when I see it. Brian didn't quote good justice, but that's what he said. You know it when you see it.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Yeah, no, it's definitely a paradigm shift and it needs definitely a some help to educate patient, caregiver, and also to help the prescriber. So it's completely right to think, Christoph, we have to think about this kind of tools. Because they're simple. The beauty here is that we are not speaking about a fancy biomarker. We are not speaking about and I spend my complete life on biomarkers but definitely this is very simple to identify these patients and to make sure that they are the right patients for our drugs which is not always the case to be very honest in medicine.
Unknown
Webcast Q&A Moderator
I think we've exhausted the questions if you want to turn it back to Remy to close things up.
Rémy Luthringer
Chief Executive Officer, Minerva Neurosciences
Yeah, so I hope it was helpful. So I hope you enjoyed it. I enjoyed it a lot because it shows what we are doing is important for patients and this is exactly what is motivating us. So we will continue, we promise that we will continue to do all what we can in order to get a successful C19 study. Things are ongoing, are going well. We are really recruiting. We are still on time for the readout of second half of next year. Obviously, when we are coming closer, we will be more precise. But today, I keep this as generic as possible because we need to work, focus, and come up with good data for the best of patients in need. So thank you again, and I think we have... Some snacks or something to eat. So you're more than welcome to stay to speak with everybody, Minerva colleagues, our KOLs. Thank you again, Christoph, Greg and Brian, and my friend Frank. So really thank you for this. Thanks for coming.